Sri Lanka High Court Grants Government Time In Drug Policy Dispute
This article was originally published in PharmAsia News
Executive SummarySri Lanka's Supreme Court has agreed to a government delay in a patients' rights group's pressure for implementation of the National Medicinal Drug Policy. The People's Movement for Patients' Rights contends the policy was adopted in the 1970s, but previous administrations declined to implement it. The current administration said last year it was considering implementation, but has been silent since, according to the State Counsel, which sought a procedural delay. The senior counsel acknowledged the failure to move on the policy violated the public's rights. (Click here for more
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.